Karen Weck, MD, FCAP, comments on PGx testing. “PGx testing has become an important tool to help clinicians select medications and prescribe an appropriate dose for certain patients,” says Dr. Weck. “AMP is committed to collaborating with the broader laboratory community to continuously improve professional PGx practices amidst this rapidly evolving molecular diagnostic landscape.”
For the full article click here: AMP Recommends Minimum Set of Pharmacogenetic Alleles to Guide Design, Development, and Validation of Clinical TPMT and NUDT15 Genotyping Assays | Newswise